RT Journal Article
T1 Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
A1 Provencio, Mariano
A1 Serna-Blasco, Roberto
A1 Franco, Fabio
A1 Calvo, Virgina
A1 Royuela, Ana
A1 Auglytė, Milda
A1 Sánchez-Hernández, Alfredo
A1 de Julián Campayo, María
A1 García-Girón, Carlos
A1 Dómine, Manuel
A1 Blasco, Ana
A1 Sánchez, José M
A1 Oramas, Juana
A1 Bosch-Barrera, Joaquim
A1 Sala, María Á
A1 Sereno, María
A1 Ortega, Ana L
A1 Chara, Luis
A1 Hernández, Berta
A1 Padilla, Airam
A1 Coves, Juan
A1 Blanco, Remedios
A1 Balsalobre, José
A1 Mielgo, Xabier
A1 Bueno, Coralia
A1 Jantus-Lewintre, Eloisa
A1 Molina-Vila, Miguel Á
A1 Romero, Atocha
K1 EGFR
K1 NSCLC
K1 Osimertinib
K1 TKI
K1 ctDNA
AB Survival data support the use of first-line osimertinib as the standard of care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). However, it remains unclear whether upfront osimertinib is superior to sequential first- or second-generation tyrosine kinase inhibitors (TKIs) followed by osimertinib for all patients. It is impossible to predict which patients are at high risk of progression, and this constitutes a major limitation of the sequential TKI approach. A total of 830 plasma samples from 228 patients with stage IV, EGFR-positive NSCLC who were treated with first-line TKIs were analysed by digital polymerase chain reaction (dPCR). The circulating tumour DNA (ctDNA) levels helped to identify patients with significantly improved survival rate, regardless of the treatment. Patients treated with first- or second-generation TKIs (N = 189) with EGFR mutations in plasma at a mutant allele frequency (MAF)  Pre-treatment ctDNA levels identify low-risk patients, who may benefit from sequential TKI treatment. Information regarding EGFR mutation clearance can help to improve patient selection.
YR 2021
FD 2021-04-05
LK http://hdl.handle.net/10668/17547
UL http://hdl.handle.net/10668/17547
LA en
DS RISalud
RD Apr 8, 2025